# Astec LifeSciences (NSE: ASTEC) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ASTEC · Pivot · prices to 22 Oct 2026

Astec LifeSciences (NSE: ASTEC) closed at ₹700.20 on 22 Oct 2026, up 6.41% on the day. With a market capitalisation of ₹1,560 Cr, it ranks 1251st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Agricultural Inputs.

Its return on equity was −20.7% in FY26. Over the past year the share price has fallen 5.5%. Its 52-week range is ₹513.40 (23 Mar 2026) to ₹941.75 (26 Nov 2025); the last close is 25.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹84 Cr (−8.3% year on year) and net profit −₹19 Cr, on a consolidated basis. Promoters held 71.96% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹700.20 |
| Market cap | ₹1,560 Cr |
| ROE | −20.7% (FY26) |
| ROCE | −10.0% (FY26) |
| Debt to equity | 1.15 |
| 52-week high | ₹941.75 (26 Nov 2025) |
| 52-week low | ₹513.40 (23 Mar 2026) |
| 1-year return | −5.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹84 Cr | −8.3% | −₹19 Cr | — | −₹8.40 |
| Q4 FY26 | ₹159 Cr | +32.7% | −₹8 Cr | — | −₹3.48 |
| Q3 FY26 | ₹125 Cr | +32.9% | −₹16 Cr | — | −₹7.04 |
| Q2 FY26 | ₹74 Cr | −25.2% | −₹24 Cr | — | −₹11.35 |
| Q1 FY26 | ₹91 Cr | +31.3% | −₹33 Cr | — | −₹16.85 |
| Q4 FY25 | ₹120 Cr | −22.3% | −₹16 Cr | — | −₹8.20 |
| Q3 FY25 | ₹94 Cr | +84.8% | −₹40 Cr | — | −₹20.59 |
| Q2 FY25 | ₹99 Cr | −11.0% | −₹39 Cr | — | −₹19.66 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹448 Cr | −₹81 Cr |
| FY25 | ₹381 Cr | −₹135 Cr |
| FY24 | ₹458 Cr | −₹47 Cr |
| FY23 | ₹628 Cr | ₹26 Cr |
| FY22 | ₹677 Cr | ₹90 Cr |
| FY21 | ₹555 Cr | ₹65 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 71.96%
- Foreign institutions: 0.01%
- Domestic institutions: 3.33%
- Non-institutions: 24.69%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Krsnaa Diagnostics](https://app.pivotnow.in/stock/KRSNAA) | ₹510.75 | ₹1,657 Cr | 16.5 | — |
| [Jupiter Life Line Hospitals](https://app.pivotnow.in/stock/JLHL) | ₹244.75 | ₹1,605 Cr | 8.3 | — |
| [Suraksha Diagnostic](https://app.pivotnow.in/stock/SURAKSHA) | ₹294.05 | ₹1,531 Cr | 47.6 | — |
| [Gujarat Kidney And Super Speciality](https://app.pivotnow.in/stock/GKSL) | ₹183.00 | ₹1,443 Cr | 73.5 | — |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹496.20 | ₹1,435 Cr | 24.8 | — |
| [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹216.03 | ₹1,422 Cr | 34.2 | — |

## Questions and answers

### What is the share price of Astec LifeSciences today?

Astec LifeSciences (NSE: ASTEC) last closed at ₹700.20 on 22 Oct 2026. Its 52-week high is ₹941.75 and its 52-week low is ₹513.40.

### What is the market cap of Astec LifeSciences?

Astec LifeSciences' market capitalisation is ₹1,560 Cr (₹1,560 Cr) at the 22 Oct 2026 close, ranking 1251st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Astec LifeSciences?

Return on equity was −20.7% in FY26 and return on capital employed was −10.0% in FY26 (consolidated figures).

### Is Astec LifeSciences a debt-free company?

No. Astec LifeSciences' debt-to-equity ratio was 1.15 in FY26, with total debt of ₹50 Cr.

### What were Astec LifeSciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Astec LifeSciences reported revenue of ₹84 Cr, −8.3% year on year, and net profit of −₹19 Cr.

### How has Astec LifeSciences stock performed over the last year?

Astec LifeSciences' share price has fallen 5.5% over the past year, +3.8% over three months and −1.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Astec LifeSciences?

As of 30 Jun 2026: promoters 71.96%, foreign institutions 0.01%, domestic institutions 3.33%, non-institutions 24.69%.

### Who are Astec LifeSciences' competitors?

The listed Pharma & Healthcare companies closest to Astec LifeSciences by market cap are Krsnaa Diagnostics, Jupiter Life Line Hospitals, Suraksha Diagnostic, Gujarat Kidney And Super Speciality, Amrutanjan Health Care and Jagsonpal Ser.

### Is Astec LifeSciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Astec LifeSciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTEC against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.